Publications by authors named "Aravind Ravi Kumar"

Claim this Profile
P
Prognostic Value of Initial Imaging and PSA Change with [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
David C Chen, James P Buteau, Nathan Papa, Tim Akhurst, Ramin Alipour, Aravind Ravi Kumar

J Nucl Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [Ga]PSMA-11 or [F]DCFPyL, [F]FDG, and [Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.
Price Jackson, James P Buteau, Lachlan McIntosh, Yu Sun, Raghava Kashyap, Aravind S Ravi Kumar

J Nucl Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lutetium-177 [Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
Louise Kostos, James P Buteau, Jing Xie, Anthony Cardin, Tim Akhurst, Aravind S Ravi Kumar

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of re-treatment with [Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.
Raghava Kashyap, Ramin Alipour, Emma Boehm, Kerry Jewell, Aravind S RaviKumar

Eur J Nucl Med Mol Imaging· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human results of terbium-161 [Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
James P Buteau, Louise Kostos, Price A Jackson, Jing Xie, Mohammad B Haskali, Aravind S Ravi Kumar

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide receptor radionuclide therapy in malignant insulinoma.
David A Pattison, Grace Kong, Timothy Akhurst, Matthew Burge, Cherie Chiang, Aravind S Ravi Kumar

Endocr Relat Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-Related Myeloid Neoplasms After [Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.
Michal Eifer, Duncan E K Sutherland, Isaac Goncalves, James P Buteau, Lewis Au, Aravind S Ravi Kumar

J Nucl Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, Jeremie Calais, Johannes Czernin

Eur Urol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Aravind Ravi Kumar

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling the Impact of Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.
Aravind S Ravi Kumar, Michael S Hofman

J Nucl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Aravind S Ravi Kumar

Endocr Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Could FAP-Targeted Molecular Imaging Replace F-FDG for Standard-of-Care Oncologic PET?
Raghava Kashyap, Aravind S Ravi Kumar

J Nucl Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Dosimetry in Lu-PSMA-617 Therapy.
Price Jackson, Michael Hofman, Lachlan McIntosh, James Patrick Buteau, Aravind Ravi Kumar

Semin Nucl Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A role of PSMA PET/CT in multimodality imaging approach in adenoid cystic carcinoma.
Nattakorn Dhiantravan, Aravind S Ravi Kumar, Karda Cavanagh, Lachlan McDowell

J Med Imaging Radiat Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?
Nattakorn Dhiantravan, Michael S Hofman, Aravind S Ravi Kumar

Eur Urol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.
Olfat Kamel Hasan, Aravind S Ravi Kumar, Grace Kong, Kira Oleinikov, Simona Ben-Haim

J Nucl Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions.
Joseph C Lee, Gemma F Hartnett, Aravind S Ravi Kumar

Eur J Nucl Med Mol Imaging· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.
Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar

Eur J Nucl Med Mol Imaging· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Aravind S Ravi Kumar, Nathan Lawrentschuk, Michael S Hofman

Curr Opin Urol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue-Ping Thang, Aravind Ravi Kumar

J Nucl Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic Insights for Optimizing PSMA Radioligand Therapy.
Aravind S Ravi Kumar, Michael S Hofman

Clin Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy.
Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst, Aravind Ravi Kumar

Eur Urol Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Setting the stage: Contemporary staging of non-melanomatous skin cancer and implementation of the new American Joint Committee on cancer eighth edition staging manual.
Georgina Casswell, Karda Cavanagh, Aravind S Ravi Kumar, Charles Giddings, Lachlan McDowell

Oral Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Amir Iravani, Benjamin Solomon, David A Pattison, Price Jackson, Aravind Ravi Kumar

Thyroid· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Isaac Goncalves, Kate Burbury, Michael Michael, Amir Iravani, Aravind S Ravi Kumar

Eur J Nucl Med Mol Imaging· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis